Avidity Biosciences develops RNA therapeutics through antibody oligonucleotide conjugates (AOC) to treat previously untreatable diseases. Lead product candidate AOC 1001 is in phase 1/2 clinical trial for myotonic dystrophy type 1. Other products in pipeline include AOC 1044 and AOC 1020, also in phase 1/2 trials. The company focuses on rare skeletal muscle and cardiac diseases. Headquartered in San Diego, California since 2012.
| Indicator | Value |
|---|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.6 |